Latest Articles : Anti-Cancer Drugs

Journal Logo

Latest Articles

The editors of this journal are pleased to offer electronic publication of accepted papers prior to print publication. These papers can be cited using the date of access and the unique DOI number. Any final changes in manuscripts will be made at the time of print publication and will be reflected in the final electronic version of the issue.

Disclaimer: Articles appearing in this Latest Articles section have been peer-reviewed and accepted for publication in this journal and posted online before print publication. Articles appearing here may contain statements, opinions, and information that have errors in facts, figures, or interpretation. Accordingly, Lippincott Williams & Wilkins, the editors and authors and their respective employees are not responsible or liable for the use of any such inaccurate or misleading data, opinion or information contained the articles in this section.

Latest Articles are available in PDF format only.

Original article

Preliminary results of randomized phase II study of etoposide plus lobaplatin or etoposide plus cisplatin with concurrent thoracic radiotherapy in the treatment of limited-stage small cell lung cancer

Wang, Mengfan; Ma, Zhu; Li, Qingsong; More

Original article

The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors

Guven, Deniz Can; Ozbek, Deniz Aral; Sahin, Taha Koray; More

Original article

Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models

El Shemerly, Mahmoud; Zanini, Elisa; Lecoultre, Marc; More

Original article

Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601

Ito, Kimihiko; Nakagawa, Mio; Shimokawa, Mototsugu; More

Case report

Sustained antitumor response to lenvatinib with weekend-off and alternate-day administration in chemotherapy-refractory thymic carcinoma: a case report

Sunaga, Noriaki; Miura, Yosuke; Sakurai, Reiko; More

Original article

Anlotinib reduces the suppressive capacity of monocytic myeloid-derived suppressor cells and potentiates the immune microenvironment normalization window in a mouse lung cancer model

Zhao, XiangFei; Zhao, RuGang; Wen, JuYi; More

Original article

Safety, tolerability, pharmacokinetics and immunogenicity of an antibody–drug conjugate (SHR-A1201) in patients with HER2-positive advanced breast cancer: an open, phase I dose-escalation study

Li, Yinjuan; Qi, Lu; Wang, Yu; More

Case report

Durable complete remission with local therapies after neoadjuvant and adjuvant nivolumab in recurrent/metastatic head and neck cancer

Cabezas-Camarero, Santiago; Iglesias-Moreno, María Cruz; Cerezo Druet, Elena; More

Original article

Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm

Bamias, Aristotelis; Zakopoulou, Roubini; Tzannis, Kimon; More